EU/3/16/1811: Orphan designation for the treatment of glioma
5-aminolevulinic acid
Table of contents
Overview
On 12 January 2017, orphan designation (EU/3/16/1811) was granted by the European Commission to Centre Hospitalier Universitaire de Lille, France, for 5-aminolevulinic acid for the treatment of glioma.
Key facts
Active substance |
5-aminolevulinic acid
|
Medicine name |
-
|
Intended use |
Treatment of glioma
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/16/1811
|
Date of designation |
12/01/2017
|
Sponsor |
Hemerion Therapeutics |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
March 2023 | The sponsor's address was updated. |
December 2020 | The sponsorship was transferred to Hemerion Therapeutics, France. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: